Table 3.
Antibody titer in blood plasma.
| Anti-IVV antibody titer in plasma (U/mL) | ||||||
|---|---|---|---|---|---|---|
| Male | Female | |||||
| Adjuvant | Saline | TNF/CHP | TNF/CHP | Saline | TNF/CHP | TNF/CHP |
| Vaccine | Saline | Saline | IVV | Saline | Saline | IVV |
| Week | ||||||
| 1 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| 2 | n.d. | n.d. | 140.0 ± 93.0 | n.d. | n.d. | 292.0 ± 146.0 |
| 4 | n.d. | n.d. | 1807.0 ± 795.0 | n.d. | n.d. | 2334.0 ± 609.0 |
| 4 + 2 | n.d. | n.d. | 7602.0 ± 2265.0 | n.d. | n.d. | 10695.0 ± 4045.0 |
The vaccine (IVV 0.3 µg/mouse) and adjuvant preparation (TNF/CHP nanoparticles 5 µg/mouse as TNF-α) were nasally administered to mice once a week up to 4 weeks. After that, 2 weeks of cessation period was set (4 + 2 weeks). Blood plasma was prepared and the anti-IVV IgG1 antibody was titrated (n = 4). n.d., not detected.